Crohn's disease is a chronic inflammatory condition of the digestive tract caused by abnormal immune reactions. It is a form of inflammatory bowel disease and can affect any part of the gastrointestinal tract from mouth to anus. The disease often follows cycles of flares and remission.
AbbVie will present new lung cancer data at WCLC 2026, including Phase 1b results for ABBV-1480 showing high response rates in NSCLC and safety updates for ABBV-706 in SCLC. The company also reported progress in dermatology, obesity, and Crohn's disease programs.
The IRA's price controls could raise long-term drug prices by 21% for the first 25 selected drugs, while Medicare's $2,000 out-of-pocket cap encourages plans to favor IV over equally effective subcutaneous versions.
AbbVie's Q2 2026 revenue hit $16.99 billion, beating estimates, but full-year EPS guidance was cut to $13.97. Growth in immunology and neuroscience continued, and the FAST study on ubrogepant wrapped up.
New research: any cardiometabolic risk factor justifies MASLD screening in overweight adults, and MASLD independently worsens sepsis, bleeding, and other outcomes in hospitalized Crohn's disease patients.
AbbVie posted record 2025 revenue of $61.2 billion and raised 2026 guidance on Skyrizi and Rinvoq growth. Pipeline advances include Crohn's submissions, obesity data, and European approval for Boey.
Abivax aligned with FDA on obefazimod NDA strategy for ulcerative colitis, targeting filing by end‑2026. Phase 3 ABTECT data at ECCO 2026 showed early symptom relief and positive DSMB safety review. Leadership appointments support potential commercialization.
A study finds end-to-side anastomosis for Crohn’s disease may reduce endoscopic recurrence, while global data show early-onset colorectal cancer has the highest GI cancer burden in young adults, with rising incidence. Both studies highlight evolving challenges and treatment options in gastroenterology.
Engineered extracellular vesicles deliver IL-2 and therapeutic antibodies with precision, reducing systemic toxicity and targeting inflamed tissues in autoimmune disease, cancer, and inflammatory bowel disease. Microfluidic electroporation enables efficient IL-2 loading, while exosome nanovesicles show efficacy in preclinical colitis models.
Celltrion released new post-hoc analysis from its phase 3 trial of Remsima SC in IBD patients at the ECCO 2026 congress. The data showed rapid clinical response after treatment gaps and maintained efficacy over 102 weeks. The company also highlighted its unique offering of infliximab in three formulations.
A retrospective study found comparable corticosteroid-free remission with upadacitinib and risankizumab in anti-TNF-exposed Crohn’s patients. Upadacitinib showed higher endoscopic remission at week 52 but more adverse events. Both JAK and IL-23 inhibitors are shaping the growing IBD treatment market.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07757217 |
Artificial Intelligence-Based Classification and Prognostic Prediction in Small Bowel Crohn's Disease |
COMPLETED | |
| NCT07753850 |
A Study of SL-325 in Crohn's Disease Patients |
NOT_YET_RECRUITING | PHASE2 |
| NCT07748338 |
Ustekinumab Real World Evidence Study |
COMPLETED | |
| NCT07697547 |
Efficacy and Safety of Low-Dose Upadacitinib Combined With Ustekinumab in the Treatment of Refractory Crohn's Disease |
COMPLETED | |
| NCT07697456 |
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis |
NOT_YET_RECRUITING | PHASE2 |
| NCT07691138 |
Stopping PPI Therapy in Inactive IBD |
RECRUITING | PHASE4 |
| NCT07677514 |
A Phase II Study of H021 Enteric-coated Tablets for Moderately to Severely Active Crohn's Disease |
NOT_YET_RECRUITING | PHASE2 |
| NCT07671313 |
Online Pain Education for Crohn's Disease and Ulcerative Colitis |
NOT_YET_RECRUITING | NA |
| NCT07663526 |
Treatment of Chinese Adult Subjects With Moderate to Severe Crohn's Disease With Tabellvi® |
NOT_YET_RECRUITING | PHASE4 |
| NCT07619547 |
Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease |
NOT_YET_RECRUITING |
